RBCC Explores New Cures for Cancer, Brain Injuries & Headaches
News Jan 31, 2012
Cutting-edge stem cell research is producing new breakthroughs that could potentially revolutionize the treatment of currently incurable diseases from cancer to brain injuries to headaches.
As the world’s population ages and the economic might of emerging countries such as China and India blossoms, the market is increasing daily for new and effective cures to old ailments. RBCC plans to capitalize on recent growth in the biosciences sector by commercializing advanced-stage research with the potential to produce new treatments.
RBCC is aiming high. The company’s current target, n3D Biosciences, has developed a breakthrough cell-culturing system that allows scientists to grow 3D stem cells that behave much more similarly to cells found in the body. This product may directly assist with advanced discoveries to find cures for common injuries and diseases.
With the help of its new allies in BioHouston, RBCC plans to identify new targets on the cutting-edge of biotechnology for acquisition and joint venture.
Single Blood Test 'CancerSEEK' Screens for Eight Cancer TypesNews
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.READ MORE
Small Compound Able to Stave Tumor and Stop its GrowthNews
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE